Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK

The FDA Wednesday approved Keytruda in recurrent or metastatic cutaneous squamous cell carcinoma that can’t be cured by surgery or radiation. Regulators based their decision on data from the Keynote-629 trial, which showed that the drug could spur a response in 34% of patients who hadn’t yet received another immunotherapy.